Iovance Biotherapeutics Shares Drop After Wider-Than-Expected 1Q Loss

Dow Jones

09 May

By Chris Wack

Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations.

The biotechnology company said it had a quarterly loss of $116.2 million, or 36 cents a share, compared with a loss of $113 million, or 42 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $77.8 million, or 24 cents a share.

Revenue for the quarter was $49.3 million, compared with last year's $715,000 and the $82.4 million analysts expected.

Iovance said its first-quarter revenue was affected by a significant reduction in capacity during an annual scheduled maintenance at its Iovance Cell Therapy Center. Full production has now resumed at the center, so the company now expects infusions to grow in the second quarter as compared with the first quarter.

For 2025, the company is looking for product revenue of $250 million to $300 million. Analysts are forecasting product revenue of $370.3 million for 2025.

As of March 31, Iovance had cash, cash equivalents, investments and restricted cash of $366 million. The current cash position and anticipated product revenue are expected to be sufficient to fund current and planned operations, including manufacturing expansion, into the second half of 2026.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

May 09, 2025 10:05 ET (14:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2534438074"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534438074\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2534438074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534438074","market":"us","top_or_hot":-1,"title":"Iovance Biotherapeutics Shares Drop After Wider-Than-Expected 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations. \n</p>\n<p>\n  The biotechnology company said it had a quarterly loss of $116.2 million, or 36 cents a share, compared with a loss of $113 million, or 42 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $77.8 million, or 24 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $49.3 million, compared with last year's $715,000 and the $82.4 million analysts expected. \n</p>\n<p>\n  Iovance said its first-quarter revenue was affected by a significant reduction in capacity during an annual scheduled maintenance at its Iovance Cell Therapy Center. Full production has now resumed at the center, so the company now expects infusions to grow in the second quarter as compared with the first quarter. \n</p>\n<p>\n  For 2025, the company is looking for product revenue of $250 million to $300 million. Analysts are forecasting product revenue of $370.3 million for 2025. \n</p>\n<p>\n  As of March 31, Iovance had cash, cash equivalents, investments and restricted cash of $366 million. The current cash position and anticipated product revenue are expected to be sufficient to fund current and planned operations, including manufacturing expansion, into the second half of 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 09, 2025 10:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Shares Drop After Wider-Than-Expected 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Shares Drop After Wider-Than-Expected 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-09 22:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations. \n</p>\n<p>\n  The biotechnology company said it had a quarterly loss of $116.2 million, or 36 cents a share, compared with a loss of $113 million, or 42 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $77.8 million, or 24 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $49.3 million, compared with last year's $715,000 and the $82.4 million analysts expected. \n</p>\n<p>\n  Iovance said its first-quarter revenue was affected by a significant reduction in capacity during an annual scheduled maintenance at its Iovance Cell Therapy Center. Full production has now resumed at the center, so the company now expects infusions to grow in the second quarter as compared with the first quarter. \n</p>\n<p>\n  For 2025, the company is looking for product revenue of $250 million to $300 million. Analysts are forecasting product revenue of $370.3 million for 2025. \n</p>\n<p>\n  As of March 31, Iovance had cash, cash equivalents, investments and restricted cash of $366 million. The current cash position and anticipated product revenue are expected to be sufficient to fund current and planned operations, including manufacturing expansion, into the second half of 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 09, 2025 10:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2534438074","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534438074","pubTimestamp":1746799500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations.The biotechnology company said it had a quarterly loss of $116.2 million, or 36 cents a share, compared with a loss of $113 million, or 42 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $77.8 million, or 24 cents a share.Revenue for the quarter was $49.3 million, compared with last year's $715,000 and the $82.4 million analysts expected.Iovance said its first-quarter revenue was affected by a significant reduction in capacity during an annual scheduled maintenance at its Iovance Cell Therapy Center. Full production has now resumed at the center, so the company now expects infusions to grow in the second quarter as compared with the first quarter.As of March 31, Iovance had cash, cash equivalents, investments and restricted cash of $366 million. The current cash position and anticipated product r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Iovance Biotherapeutics第一季度亏损超出预期后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Iovance Biotherapeutics shares were 42% lower, at $1.84, after the company said its first-quarter loss was wider than analysts' expectations. \n\n\n  The biotechnology company said it had a quarterly loss of $116.2 million, or 36 cents a share, compared with a loss of $113 million, or 42 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $77.8 million, or 24 cents a share. \n\n\n  Revenue for the quarter was $49.3 million, compared with last year's $715,000 and the $82.4 million analysts expected. \n\n\n  Iovance said its first-quarter revenue was affected by a significant reduction in capacity during an annual scheduled maintenance at its Iovance Cell Therapy Center. Full production has now resumed at the center, so the company now expects infusions to grow in the second quarter as compared with the first quarter. \n\n\n  For 2025, the company is looking for product revenue of $250 million to $300 million. Analysts are forecasting product revenue of $370.3 million for 2025. \n\n\n  As of March 31, Iovance had cash, cash equivalents, investments and restricted cash of $366 million. The current cash position and anticipated product revenue are expected to be sufficient to fund current and planned operations, including manufacturing expansion, into the second half of 2026. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 09, 2025 10:05 ET (14:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}